Page 25 - CBAC Newsletter 2016

112. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal
113. cells. Eur J Pharmacol. 336, 243-249, 1997.
114.
115. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by
116. the novel anticonvulsant retigabine. Mol Pharmacol. 58, 253-262, 2000.
117.
118. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of
KCNQ2/Q3 potassium channels. Mol Pharmacol. 58, 591-600, 2000.
119.
Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener:
120. pharmacological and clinical data. Expert Opin Pharmacother. 13, 1807-1816, 2012.

121. Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons:
changes in electroresponsive properties and synaptic transmission. Mol Pharmacol. 61, 921-927, 2002.
122.
123. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, Schwake M. Molecular determinants of
124. KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J. Neurosci. 25, 5051-5060, 2005.
125.
126. Lange W, Geissendorfer J, Schenzer A, Grotzinger J, Seebohm G, Friedrich T, Schwake M. Refinement of the
binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol.
127. 75, 272-280, 2009.

128. Boehlen A, Schwake M, Dost R, Kunert A, Fidzinski P, Heinemann U, Gebhardt C. The new KCNQ2 activator
4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. Br J Pharmacol.
129. 168, 1182-1200, 2013.

Gao Z, Zhang T, Wu M, Xiong Q, Sun H, Zhang Y, Zu L, Wang W, Li M. Isoform-specific prolongation of Kv7
(KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel
interactions. J Biol Chem. 285, 28322-28332, 2010.

Peretz A, Degani-Katzav N, Talmon M, Danieli E, Gopin A, Malka E, Nachman R, Raz A, Shabat D, Attali B.
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new
diphenylamine derivatives. PloS One. 2, e1332, 2007.

Xiong Q, Gao Z, Wang W, Li M. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic
compounds. Trends Pharmacol Sci. 29, 99-107, 2008.

Kim RY, Yau MC, Galpin JD, Seebohm G, Ahern CA, Pless SA, Kurata HT. Atomic basis for therapeutic
activation of neuronal potassium channels. Nat Commun. 6, 8116, 2015.

Jankovic S, Ilickovic I. The preclinical discovery and development of ezogabine for the treatment of epilepsy.
Expert Opin Drug Discov. 8, 1429-1437, 2013.

Greenwood IA, Ohya S. New tricks for old dogs: KCNQ expression and role in smooth muscle. Br J Pharmacol.
156, 1196-1203, 2009.

Martyn-St James M, Glanville J, McCool R, Duffy S, Cooper J, Hugel P, Lane PW. The efficacy and safety of
retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and
indirect comparison. Seizure. 21, 665-678, 2012.

Kalappa BI, Soh H, Duignan KM, Furuya T, Edwards S, Tzingounis AV, Tzounopoulos T. Potent
KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development
of tinnitus. J Neurosci. 35, 8829-8842, 2015.

Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, Jentsch TJ. KCNQ4, a K+ channel
mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway.
Proc Natl Acad Sci. USA. 97, 4333-4338, 2000.

Iannotti FA, Barrese V, Formisano L, Miceli F, Taglialatela M. Specification of skeletal muscle differentiation by
repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels.
Mol Biol Cell. 24, 274-284, 2013.

CBAC Center Heartbeat | 21